DT-109 Compound Overview
DT-109 (Gly-Gly-Leu) is an investigational tripeptide compound that is NOT approved for clinical use in treating metabolic liver disease, despite promising preclinical data in nonhuman primates and mice showing reversal of steatohepatitis and fibrosis. 1, 2
What is DT-109?
DT-109 is a glycine-based tripeptide (Gly-Gly-Leu) currently under investigation for metabolic dysfunction-associated steatohepatitis (MASH). The compound has demonstrated efficacy in preclinical models through multiple mechanisms:
- Hepatic effects: Stimulates fatty acid degradation, enhances glutathione formation, and reverses hepatic steatosis 1
- Gut-liver axis modulation: Reduces Clostridium perfringens abundance, lowers intestinal ammonia production, and restores intestinal barrier integrity 2
- Immune regulation: Suppresses CD8+ T cell-mediated hepatic cytotoxicity by reducing FosB-mediated CCL5 upregulation 2
- Microbial effects: Modulates bile acid metabolism through changes in gut microbiota 1
Current Regulatory Status
DT-109 has NOT received FDA approval or any regulatory authorization for clinical use. The compound remains in preclinical development stages. The most advanced evidence comes from nonhuman primate studies, not human clinical trials 1, 2.
Important Distinction from Approved Therapies
The 2024 EASL-EASD-EASO guidelines for MASLD management do NOT mention DT-109 among recommended therapies 3. Currently approved or recommended options include:
- Resmetirom: The only agent with strong recommendation for non-cirrhotic MASH with significant fibrosis (stage ≥2) based on phase III trial data 3
- GLP-1 receptor agonists: Safe for use in MASH for their approved indications (diabetes, obesity) but not as MASH-targeted therapy 3
- Lifestyle modifications: Diet quality improvement and physical activity remain foundational 3
Preclinical Evidence Strength
While DT-109 shows promise, several critical gaps exist:
- No human clinical trial data on safety, efficacy, or dosing
- No phase I, II, or III trial results published
- Lack of long-term safety data even in animal models
- Unknown sustainability of histological benefits
- No data on liver-related clinical outcomes (decompensation, hepatocellular carcinoma, mortality)
The nonhuman primate studies used doses of 150 mg/kg/day 1, 4, but human equivalent dosing remains undefined.
Clinical Practice Implications
Do not prescribe or recommend DT-109 for MASH/MASLD treatment. The compound is not commercially available and lacks regulatory approval. For patients with MASLD requiring pharmacotherapy:
- First-line: Consider resmetirom if locally approved for non-cirrhotic MASH with fibrosis stage ≥2 3
- Metabolic comorbidities: Use GLP-1 agonists, SGLT2 inhibitors, or metformin for their approved indications (diabetes, obesity, heart failure) 3
- Foundation: Emphasize Mediterranean-style diet, limit ultra-processed foods, and recommend ≥150 minutes/week moderate-intensity physical activity 3
Common Pitfall to Avoid
Do not confuse investigational compounds showing preclinical promise with clinically validated therapies. The translational gap from animal models to human efficacy remains substantial in MASH drug development, as evidenced by multiple recent clinical trial failures despite positive preclinical data 1.
Future Outlook
The authors of the DT-109 studies explicitly state the need for "clinical evaluation" 1 and acknowledge that their work describes a "highly translatable NASH model" but does not constitute clinical evidence. Until human clinical trials demonstrate safety and efficacy, DT-109 remains a research tool, not a therapeutic option.